Cabotegravir/rilpivirine (Cabenuva) vs Dolutegravir
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
Cabotegravir/rilpivirine (Cabenuva)
Marketed by GlaxoSmithKline
NCT05917509 · Phase 3 · completed
The 171 participants were assigned to active treatment groups without randomization or blinding, which limits the reliability of comparisons between the regimens. The primary outcomes measured virologic suppression. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: March 2027 · NCT06411223 (registry estimate)
Reported efficacy
Percentage of Participants With Plasma Human Immunodeficiency Virus-ribonucleic Acid (HIV-RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Week 48: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results). (met)
Result source: NCT03299049
Dolutegravir · Tivicay / Triumeq / Dovato / Juluca (component)
Marketed by GlaxoSmithKline and partners
NCT01263015 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled phase 3 trial in 833 participants comparing dolutegravir plus abacavir/lamivudine to Atripla. The primary endpoint of virologic suppression (<50 copies/mL) at week 48 was a hard clinical measure, and the comparison was statistically significant in favor of dolutegravir (88% vs 81%, p=0.003), with the confidence interval excluding zero. The trial was adequately powered and the primary outcome was met, supporting a strong evidence grade.
Next expected readout: November 2026 · NCT04892654 (registry estimate)
Reported efficacy
Proportion of Subjects Responding Based on Plasma HIV-1 RNA <50 c/mL at Week 48: Week 48 HIV-1 RNA <50 c/mL: 88% with dolutegravir plus abacavir/lamivudine vs 81% with Atripla; difference 7.3 percentage points (95% CI 2.3 to 12.2; p=0.003). (met)
Result source: NCT01263015
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cabotegravir/rilpivirine (Cabenuva) | Dolutegravir |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 94% vs 91%vs CAB 30 mg+ABC/3TCNCT02120352125 other results
| 88% vs 85%vs RTGNCT0122782412 other results
|
| HIV-1 RNA 50 copies/mL or more (week 48) | 0% vs 0%vs DTG + RPVNCT03639311 | —Not posted · NCT01837277 |
| CD4 count, change (week 48) | 270.6 vs 369.9vs CAB 30 mg+ABC/3TCNCT0212035236 other results
| 163 vs 174−11 vs placeboNCT0156889244 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Cabotegravir/rilpivirine (Cabenuva)
- 94% vs 91%vs CAB 30 mg+ABC/3TCNCT02120352
125 other results
- 95% vs 91% NCT02120352
- 80% vs 71% NCT01641809
- 87% vs 71% NCT01641809
- 80% vs 71% NCT01641809
- 67% vs 0% NCT01641809
- 70% vs 0% NCT01641809
- 63% vs 0% NCT01641809
- 73% vs 0% NCT01641809
- 65% vs 0% NCT01641809
- 72% vs 0% NCT01641809
- 67% vs 0% NCT01641809
- 75% vs 63% NCT01641809
- 65% vs 0% NCT01641809
- 85% vs 83% NCT01641809
- 75% vs 68% NCT01641809
- 62% vs 0% NCT01641809
- 85% vs 89% NCT01641809
- 73% vs 68% NCT01641809
- 63% vs 0% NCT01641809
- 83% vs 89% NCT01641809
- 73% vs 68% NCT01641809
- 63% vs 0% NCT01641809
- 83% vs 89% NCT01641809
- 80% vs 71% NCT01641809
- 62% vs 0% NCT01641809
- 91% vs 94% NCT01641809
- 82% vs 68% NCT01641809
- 92% vs 89% NCT01641809
- 82% vs 71% NCT01641809
- 62% vs 0% NCT01641809
- 92% vs 94% NCT01641809
- 80% vs 69% NCT01641809
- 91% vs 91% NCT01641809
- 78% vs 69% NCT01641809
- 89% vs 91% NCT01641809
- 75% vs 66% NCT01641809
- 85% vs 87% NCT01641809
- 85% vs 74% NCT01641809
- 62% vs 0% NCT01641809
- 94% vs 96% NCT01641809
- 62% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 60% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 77% vs 0% NCT01641809
- 80% vs 0% NCT01641809
- 80% vs 0% NCT01641809
- 80% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 80% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 84% vs 63% NCT01641809
- 74% vs 0% NCT01641809
- 93% vs 83% NCT01641809
- 85% vs 68% NCT01641809
- 75% vs 0% NCT01641809
- 95% vs 89% NCT01641809
- 85% vs 68% NCT01641809
- 77% vs 0% NCT01641809
- 95% vs 89% NCT01641809
- 85% vs 68% NCT01641809
- 75% vs 0% NCT01641809
- 95% vs 89% NCT01641809
- 87% vs 71% NCT01641809
- 74% vs 0% NCT01641809
- 96% vs 94% NCT01641809
- 85% vs 68% NCT01641809
- 95% vs 89% NCT01641809
- 85% vs 71% NCT01641809
- 75% vs 0% NCT01641809
- 95% vs 94% NCT01641809
- 87% vs 69% NCT01641809
- 96% vs 91% NCT01641809
- 85% vs 69% NCT01641809
- 95% vs 91% NCT01641809
- 85% vs 66% NCT01641809
- 95% vs 87% NCT01641809
- 87% vs 74% NCT01641809
- 75% vs 0% NCT01641809
- 96% vs 96% NCT01641809
- 70% vs 0% NCT01641809
- 74% vs 0% NCT01641809
- 70% vs 0% NCT01641809
- 70% vs 0% NCT01641809
- 58% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 58% vs 0% NCT01641809
- 65% vs 0% NCT01641809
- 57% vs 0% NCT01641809
- 68% vs 0% NCT01641809
- 58% vs 0% NCT01641809
- 68% vs 63% NCT01641809
- 57% vs 0% NCT01641809
- 79% vs 83% NCT01641809
- 72% vs 68% NCT01641809
- 55% vs 0% NCT01641809
- 83% vs 89% NCT01641809
- 72% vs 68% NCT01641809
- 55% vs 0% NCT01641809
- 83% vs 89% NCT01641809
- 78% vs 68% NCT01641809
- 53% vs 0% NCT01641809
- 90% vs 89% NCT01641809
- 80% vs 71% NCT01641809
- 50% vs 0% NCT01641809
- 92% vs 94% NCT01641809
- 83% vs 68% NCT01641809
- 96% vs 89% NCT01641809
- 85% vs 71% NCT01641809
- 52% vs 0% NCT01641809
- 98% vs 94% NCT01641809
- 83% vs 69% NCT01641809
- 96% vs 91% NCT01641809
- 85% vs 69% NCT01641809
- 98% vs 91% NCT01641809
- 78% vs 66% NCT01641809
- 90% vs 87% NCT01641809
- 87% vs 74% NCT01641809
- 53% vs 0% NCT01641809
- 96% vs 96% NCT01641809
- 52% vs 0% NCT01641809
- 50% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 98% vs 100% NCT03639311
- Dolutegravir
- 88% vs 85%vs RTGNCT01227824
12 other results
- 90% vs 83% NCT01449929
- 88% vs 81% NCT01263015
- 90% vs 93% NCT02831673
- 93% vs 94% NCT02831764
- 71% vs 63% NCT01263015
- 77% vs 70% NCT01263015
- 79% vs 83% NCT02831673
- 84% vs 84% NCT02831764
- 84% vs 89% NCT02831673
- 88% vs 90% NCT02831764
- 92% vs 93% NCT02831673
- 94% vs 94% NCT02831764
HIV-1 RNA 50 copies/mL or more (week 48)
- Cabotegravir/rilpivirine (Cabenuva)
- 0% vs 0%vs DTG + RPVNCT03639311
- Dolutegravir
- —Not posted · NCT01837277
CD4 count, change (week 48)
- Cabotegravir/rilpivirine (Cabenuva)
- 270.6 vs 369.9vs CAB 30 mg+ABC/3TCNCT02120352
36 other results
- 263.7 vs 346.1 NCT02120352
- 257.5 vs 369.9 NCT02120352
- 264.4 vs 346.1 NCT02120352
- 267.5 vs 281.7 NCT01641809
- 287 vs 279.4 NCT01641809
- 201.4 vs 257.1 NCT01641809
- 269.4 vs 263.8 NCT01641809
- 241.6 vs 262.5 NCT01641809
- 212.8 vs 221.5 NCT01641809
- 213 vs 185.2 NCT01641809
- 205.2 vs 197.4 NCT01641809
- 188.1 vs 178.2 NCT01641809
- 177.7 vs 166.4 NCT01641809
- 180.9 vs 143.4 NCT01641809
- 286.2 vs 281.7 NCT01641809
- 278.1 vs 279.4 NCT01641809
- 254 vs 257.1 NCT01641809
- 266.1 vs 263.8 NCT01641809
- 259 vs 262.5 NCT01641809
- 212.3 vs 221.5 NCT01641809
- 265 vs 185.2 NCT01641809
- 209.9 vs 197.4 NCT01641809
- 193.3 vs 178.2 NCT01641809
- 194.7 vs 166.4 NCT01641809
- 204 vs 143.4 NCT01641809
- 269.4 vs 281.7 NCT01641809
- 261.5 vs 279.4 NCT01641809
- 232 vs 257.1 NCT01641809
- 217.7 vs 263.8 NCT01641809
- 235.1 vs 262.5 NCT01641809
- 203.6 vs 221.5 NCT01641809
- 192 vs 185.2 NCT01641809
- 191.4 vs 197.4 NCT01641809
- 205 vs 178.2 NCT01641809
- 186.4 vs 166.4 NCT01641809
- 172.5 vs 143.4 NCT01641809
- Dolutegravir
- 163 vs 174−11 vs placeboNCT01568892
44 other results
- 170 vs 146 NCT01568892
- 115 vs 156 NCT01568892
- 90.5 vs 125.5 NCT01568892
- 48 vs 135.5 NCT01568892
- 39 vs 117 NCT01568892
- 292.2 vs 286.2 NCT01227824
- 281.3 vs 292.9 NCT01227824
- 247.8 vs 278.6 NCT01227824
- 247.8 vs 264.2 NCT01227824
- 238.9 vs 257.5 NCT01227824
- 248.8 vs 230.7 NCT01910402
- 224.1 vs 239.8 NCT01227824
- 230.7 vs 191.4 NCT01910402
- 223.4 vs 241.3 NCT01227824
- 199.3 vs 204.2 NCT01227824
- 200.6 vs 163 NCT01910402
- 322.6 vs 286 NCT01263015
- 315.2 vs 272.1 NCT01263015
- 349.3 vs 298.9 NCT01263015
- 306.1 vs 269.6 NCT01263015
- 347 vs 311 NCT01263015
- 271.3 vs 235.3 NCT01263015
- 377.9 vs 327.2 NCT01263015
- 378.5 vs 331.6 NCT01263015
- 267.5 vs 209.5 NCT01263015
- 379.5 vs 333.3 NCT01263015
- 265.5 vs 216.2 NCT01263015
- 250.5 vs 208.1 NCT01263015
- 216.9 vs 177.8 NCT01263015
- 264.7 vs 253.8 NCT02831673
- 272 vs 264.6 NCT02831764
- 265 vs 230 NCT02259127
- 311 vs 230 NCT02259127
- 228 vs 230 NCT02259127
- 222.2 vs 217.7 NCT02831673
- 301.8 vs 303.2 NCT02831673
- 225.7 vs 217.2 NCT02831764
- 301.7 vs 296.6 NCT02831764
- 192.2 vs 175.1 NCT02831673
- 188.8 vs 163.2 NCT02831764
- 72 vs 230 NCT02259127
- 39 vs 28 NCT02263326
- 88 vs 75 NCT03991013
- 111 vs 101 NCT03851588
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety
Coverage. Cabotegravir/rilpivirine (Cabenuva): 13 of 13 rows · Dolutegravir: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Cabotegravir/rilpivirine (Cabenuva) Rows use multiple source trials | Dolutegravir Rows use multiple source trials |
|---|---|---|
| CD4+ absolute change · cells/uL Induction | 142.2 vs 135.5 Efavirenz cells/uL @ 16wk30 mga,b,c,d NCT01641809 · Phase 2 · registry result, not featured evidence · pooled show 2 more doses148.3 vs 135.5 Efavirenz cells/uL @ 16wk60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 159.3 vs 135.5 Efavirenz cells/uL @ 16wk10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled | 214.7 vs 174.1 EFV/TDF/FTC cells/uL @ 16wk50 mg plus 600/300 mg once dailyb,c,d NCT01263015 · Phase 3 · combination · HIV · phase 3 2 other source trials155.1 vs 173 RTG cells/uL @ 16wk50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 76.5 vs 70 placebo cells/uL @ 16wk50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence |
| CD4+ absolute change · cells/uL No placebo or comparator arm | 348.6 cells/uL @ 180wk30 mga,b,c,e NCT01641809 · Phase 2 · registry result, not featured evidence · pooled show 2 more doses384.2 cells/uL @ 180wk60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 338 cells/uL @ 180wk10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled | 170.5 cells/uL @ 180wk50 mg BIDb,c,e NCT01328041 · Phase 3 |
| CD4+ Cell event count · cells/uL Maintenance | 750 vs 906.8 CAB 30 mg+ABC/3TC cells/uL @ 96wkIM-Q4Wa,b,c NCT02120352 · Phase 2 · registry result, not featured evidence · combination show 1 more dose748.6 vs 906.8 CAB 30 mg+ABC/3TC cells/uL @ 96wkIM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination | 732.8 vs 711.5 DTG + TDF/FTC cells/uL @ 96wkb,c NCT02831673 · Phase 3 · registry result, not featured evidence · combination 1 other source trial734.9 vs 739.9 DTG + TDF/FTC cells/uL @ 96wk NCT02831764 · Phase 3 · registry result, not featured evidence · combination |
| HIV-1 RNA absolute change · log Induction | -2.659 vs -2.602 Efavirenz log @ 16wk30 mga,b,c,d NCT01641809 · Phase 2 · registry result, not featured evidence · pooled show 2 more doses-2.815 vs -2.602 Efavirenz log @ 16wk60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled -2.823 vs -2.602 Efavirenz log @ 16wk10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled | -3.03 vs -2.98 EFV/TDF/FTC log @ 16wk50 mg plus 600/300 mg once dailyb,c,d NCT01263015 · Phase 3 · combination · HIV · phase 3 3 other source trials-2.917 vs -2.943 RTG log @ 16wk50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 -2.86 vs -2.71 DRV + RTV log @ 16wk50 mg once daily NCT01449929 · Phase 3 -1.48 vs -2.24 placebo log @ 16wk50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence |
| HIV-1 RNA absolute change · log Maintenance | -2.89 vs -2.77 CAB 30 mg+ABC/3TC log @ 96wkIM-Q4Wa,b,c NCT02120352 · Phase 2 · registry result, not featured evidence · combination show 1 more dose-2.77 vs -2.77 CAB 30 mg+ABC/3TC log @ 96wkIM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination | -2.99 vs -3.06 EFV/TDF/FTC log @ 96wk50 mg plus 600/300 mg once dailyb,c NCT01263015 · Phase 3 · combination · HIV · phase 3 1 other source trial-2.938 vs -2.901 RTG log @ 96wk50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 |
| HIV-1 RNA absolute change · log No placebo or comparator arm | -2.628 log @ 180wk30 mga,b,c,e NCT01641809 · Phase 2 · registry result, not featured evidence · pooled show 2 more doses-2.767 log @ 180wk60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled -2.747 log @ 180wk10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled | -2.425 log @ 180wk50 mg BIDb,c,e NCT01328041 · Phase 3 |
| HIV-1 RNA Less Than 400 Copies responder rate · % of participants Maintenance | 85% (n=60) vs 73% (n=62) Efavirenz @ 48wk30 mga,b,c,e NCT01641809 · Phase 2 · registry result, not featured evidence · pooled show 2 more doses89% (n=61) vs 73% (n=62) Efavirenz @ 48wk60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 83% (n=60) vs 73% (n=62) Efavirenz @ 48wk10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled | 92% (n=242) vs 87% (n=242) DRV + RTV @ 48wk50 mg once dailyb,c,e NCT01449929 · Phase 3 |
| HIV-1 RNA Level absolute value · log Maintenance | 1.59 vs 1.61 CAB 30 mg+ABC/3TC log @ 32wkIM-Q4Wa,b,c,e NCT02120352 · Phase 2 · registry result, not featured evidence · combination show 1 more dose1.6 vs 1.61 CAB 30 mg+ABC/3TC log @ 32wkIM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination | 2.72 vs 1.81 placebo log @ 32wk50 mg BIDb,c,e NCT01568892 · Phase 3 · registry result, not featured evidence |
| HIV-1 RNA LT 50 Copies responder rate · % of participants No placebo or comparator arm | 100% (n=115) @ 130wkc,e,f NCT04001803 · Phase 3 · registry result, not featured evidence | 100% (n=149) @ 432wkc,e,f NCT01910402 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 13.6%g NCT04982445 · Phase 4 · registry result, not featured evidence show 45 more results—400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 1.1%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 8.6%Direct to Injections (D2I) NCT04542070 · Phase 3 · registry result, not featured evidence 13.1%Oral lead-in Phase (OLI) NCT04542070 · Phase 3 · registry result, not featured evidence —Q2M NCT04542070 · Phase 3 · registry result, not featured evidence 6.5% NCT04399551 · Phase 3 · registry result, not featured evidence 11.3% NCT04001803 · Phase 3 · registry result, not featured evidence 1.3%CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —Step 2: CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 15.6%Q2M NCT03639311 · Phase 2 · registry result, not featured evidence · combination 11.7%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.8%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 13.3%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 12.5%30 mg NCT00920426 · Phase 2 · registry result, not featured evidence —5 mg NCT00920426 · Phase 2 · registry result, not featured evidence 15.2%30 mg NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4h (C4h) CAB200 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 1: Cohort 4h (C4h) CAB400 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 2: Cohort 5 (C5) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 2: Cohort 5 (C5) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —30 mg NCT03149848 · Phase 1 · registry result, not featured evidence —300 mg + 30 mg NCT03149848 · Phase 1 · registry result, not featured evidence · combination | 17.4%50 mg plus 600/300 mg once dailyh NCT01263015 · Phase 3 · combination · HIV · phase 3 show 41 more results26%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 —50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 13.6%50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 31.1%50 mg BID NCT01328041 · Phase 3 8.5% NCT04880395 · Phase 4 · registry result, not featured evidence · combination 10.7% NCT04585737 · Phase 4 · registry result, not featured evidence 25.6%Abacavir/Dolutegravir/Lamivudine(A NCT03016533 · Phase 3 · registry result, not featured evidence · combination 13.1%Dolutegravir (DTG) NCT03016533 · Phase 3 · registry result, not featured evidence —DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 17.6%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence —DTG + 3TC-Continuation Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination 16.2%DTG + 3TC-Double Blind Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC-Double-blind Phase + Ope NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Continuation Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination 11.4%DTG + 3TC - Double-blind Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Double-blind Phase + O NCT02831764 · Phase 3 · registry result, not featured evidence · combination 7.8%Arm 1: Maternal DTG+FTC/TAF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 4.7%Arm 2: Maternal DTG+FTC/TDF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT02263326 · Phase 3 · registry result, not featured evidence · combination 15.4%50 mg OD NCT01499199 · Phase 3 · registry result, not featured evidence 0%50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence —50mg BID NCT01568892 · Phase 3 · registry result, not featured evidence 0%Dolutegravir (<14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence 0%Dolutegravir (>=14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY A (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY B (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence 23.9% NCT01837277 · Phase 2/3 · registry result, not featured evidence 0%50 mg od NCT02245022 · Phase 2/3 · registry result, not featured evidence 6.7%50 mg BID NCT05630872 · Phase 2 · registry result, not featured evidence 1.5% NCT03991013 · Phase 2 · registry result, not featured evidence 3.8% NCT03851588 · Phase 2 · registry result, not featured evidence —Cohort 1 Stratum 1A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1B NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1C NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2B NCT05406583 · Phase 1 · registry result, not featured evidence —Arm 1 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence —Arm 2 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence 0%50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —g NCT04982445 · Phase 4 · registry result, not featured evidence show 45 more results—400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 1.1%Direct to Injections (D2I) NCT04542070 · Phase 3 · registry result, not featured evidence 5.7%Oral lead-in Phase (OLI) NCT04542070 · Phase 3 · registry result, not featured evidence —Q2M NCT04542070 · Phase 3 · registry result, not featured evidence 3.5% NCT04399551 · Phase 3 · registry result, not featured evidence 4.3% NCT04001803 · Phase 3 · registry result, not featured evidence —CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —Step 2: CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 1.1%Q2M NCT03639311 · Phase 2 · registry result, not featured evidence · combination 1.7%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 4.9%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 0%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 12.5%30 mg NCT00920426 · Phase 2 · registry result, not featured evidence —5 mg NCT00920426 · Phase 2 · registry result, not featured evidence —30 mg NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4h (C4h) CAB200 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 1: Cohort 4h (C4h) CAB400 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 2: Cohort 5 (C5) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 2: Cohort 5 (C5) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —30 mg NCT03149848 · Phase 1 · registry result, not featured evidence —300 mg + 30 mg NCT03149848 · Phase 1 · registry result, not featured evidence · combination | 3.1%50 mg plus 600/300 mg once dailyh NCT01263015 · Phase 3 · combination · HIV · phase 3 show 41 more results2.9%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 —50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 2.1%50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 3.8%50 mg BID NCT01328041 · Phase 3 — NCT04880395 · Phase 4 · registry result, not featured evidence · combination — NCT04585737 · Phase 4 · registry result, not featured evidence —Abacavir/Dolutegravir/Lamivudine(A NCT03016533 · Phase 3 · registry result, not featured evidence · combination —Dolutegravir (DTG) NCT03016533 · Phase 3 · registry result, not featured evidence —DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 4%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence —DTG + 3TC-Continuation Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination 2.8%DTG + 3TC-Double Blind Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC-Double-blind Phase + Ope NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Continuation Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination 2.8%DTG + 3TC - Double-blind Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Double-blind Phase + O NCT02831764 · Phase 3 · registry result, not featured evidence · combination —Arm 1: Maternal DTG+FTC/TAF NCT03048422 · Phase 3 · registry result, not featured evidence · combination —Arm 2: Maternal DTG+FTC/TDF NCT03048422 · Phase 3 · registry result, not featured evidence · combination — NCT02263326 · Phase 3 · registry result, not featured evidence · combination 7.7%50 mg OD NCT01499199 · Phase 3 · registry result, not featured evidence —50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence —50mg BID NCT01568892 · Phase 3 · registry result, not featured evidence —Dolutegravir (<14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir (>=14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY A (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY B (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence — NCT01837277 · Phase 2/3 · registry result, not featured evidence —50 mg od NCT02245022 · Phase 2/3 · registry result, not featured evidence —50 mg BID NCT05630872 · Phase 2 · registry result, not featured evidence — NCT03991013 · Phase 2 · registry result, not featured evidence — NCT03851588 · Phase 2 · registry result, not featured evidence —Cohort 1 Stratum 1A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1B NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1C NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2B NCT05406583 · Phase 1 · registry result, not featured evidence —Arm 1 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence —Arm 2 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence —50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 0%g NCT04982445 · Phase 4 · registry result, not featured evidence show 45 more results0%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 0%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 1.1%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 3.6%Direct to Injections (D2I) NCT04542070 · Phase 3 · registry result, not featured evidence 6.3%Oral lead-in Phase (OLI) NCT04542070 · Phase 3 · registry result, not featured evidence 3.4%Q2M NCT04542070 · Phase 3 · registry result, not featured evidence 4% NCT04399551 · Phase 3 · registry result, not featured evidence 7.8% NCT04001803 · Phase 3 · registry result, not featured evidence —CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination 12.7%Step 2: CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination 27%IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 10%IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 27%IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 26.5%IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 11.1%Q2M NCT03639311 · Phase 2 · registry result, not featured evidence · combination —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 0%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.4%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 17%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 3.3%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.1%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.8%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 3.3%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.6%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 15.2%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 0%30 mg NCT00920426 · Phase 2 · registry result, not featured evidence 0%5 mg NCT00920426 · Phase 2 · registry result, not featured evidence 0%30 mg NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 1 (C1) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 1 (C1) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 2 (C2) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 2 (C2) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 3 (C3) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 12.5%Part 1: Cohort 3 (C3) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 4 (C4) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 4 (C4) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 4h (C4h) CAB200 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination 0%Part 1: Cohort 4h (C4h) CAB400 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination 0%Part 2: Cohort 5 (C5) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 2: Cohort 5 (C5) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%30 mg NCT03149848 · Phase 1 · registry result, not featured evidence 7.1%300 mg + 30 mg NCT03149848 · Phase 1 · registry result, not featured evidence · combination | 15.7%50 mg plus 600/300 mg once dailyh NCT01263015 · Phase 3 · combination · HIV · phase 3 show 41 more results10%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 6.2%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 —50 mg once daily NCT01449929 · Phase 3 14.9%50 mg once daily NCT01449929 · Phase 3 3.3%50 mg once daily NCT01449929 · Phase 3 25.1%50 mg BID NCT01328041 · Phase 3 9.9% NCT04880395 · Phase 4 · registry result, not featured evidence · combination 8.1% NCT04585737 · Phase 4 · registry result, not featured evidence 7.7%Abacavir/Dolutegravir/Lamivudine(A NCT03016533 · Phase 3 · registry result, not featured evidence · combination 8.2%Dolutegravir (DTG) NCT03016533 · Phase 3 · registry result, not featured evidence 8.7%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 4.8%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 2.1%DTG + 3TC-Continuation Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC-Double Blind Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination 10.4%DTG + 3TC-Double-blind Phase + Ope NCT02831673 · Phase 3 · registry result, not featured evidence · combination 3.6%DTG + 3TC - Continuation Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Double-blind Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination 10.8%DTG + 3TC - Double-blind Phase + O NCT02831764 · Phase 3 · registry result, not featured evidence · combination 18%Arm 1: Maternal DTG+FTC/TAF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 18.1%Arm 2: Maternal DTG+FTC/TDF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT02263326 · Phase 3 · registry result, not featured evidence · combination 15.4%50 mg OD NCT01499199 · Phase 3 · registry result, not featured evidence —50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence 35.7%50mg BID NCT01568892 · Phase 3 · registry result, not featured evidence 26.2%Dolutegravir (<14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence 10%Dolutegravir (>=14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence 14.9%Dolutegravir - ODYSSEY A (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence 6.1%Dolutegravir - ODYSSEY B (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence 9.8% NCT01837277 · Phase 2/3 · registry result, not featured evidence 6.9%50 mg od NCT02245022 · Phase 2/3 · registry result, not featured evidence 6.7%50 mg BID NCT05630872 · Phase 2 · registry result, not featured evidence 3.1% NCT03991013 · Phase 2 · registry result, not featured evidence 0% NCT03851588 · Phase 2 · registry result, not featured evidence 0%Cohort 1 Stratum 1A NCT05406583 · Phase 1 · registry result, not featured evidence 0%Cohort 1 Stratum 1B NCT05406583 · Phase 1 · registry result, not featured evidence 0%Cohort 1 Stratum 1C NCT05406583 · Phase 1 · registry result, not featured evidence 7.1%Cohort 2 Stratum 2A NCT05406583 · Phase 1 · registry result, not featured evidence 0%Cohort 2 Stratum 2B NCT05406583 · Phase 1 · registry result, not featured evidence 0%Arm 1 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence 0%Arm 2 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence 0%50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | g injection site discomfort 13.6% injection site pain 13.6% fatigue 2.3% NCT04982445 · Phase 4 · registry result, not featured evidence show 40 more results400 mg + 600 mg Q4W injection site pain 32.3% injection site nodule 9.7% injection site induration 2.2% NCT05896748 · Phase 3 · registry result, not featured evidence · combination 400 mg + 600 mg Q4W injection site pain 74.2% injection site nodule 64.5% injection site erythema 51.6% NCT05896748 · Phase 3 · registry result, not featured evidence · combination 400 mg + 600 mg Q4W injection site pain 30.9% injection site nodule 3.2% injection site pruritus 2.1% NCT05896748 · Phase 3 · registry result, not featured evidence · combination injection site pain 65.2% covid-19 17.9% headache 12.5% NCT04542070 · Phase 3 · registry result, not featured evidence injection site pain 60.6% covid-19 19.4% injection site induration 11.4% NCT04542070 · Phase 3 · registry result, not featured evidence Q2M injection site pain 37.9% covid-19 14.5% arthralgia 0% NCT04542070 · Phase 3 · registry result, not featured evidence injection site pain 80.2% covid-19 18.4% injection site induration 11.2% NCT04399551 · Phase 3 · registry result, not featured evidence injection site pain 55.7% injection site discomfort 26.1% fatigue 20% NCT04001803 · Phase 3 · registry result, not featured evidence creatinine renal clearance decreased 19.7% lipase increased 11.3% chills 7% NCT03739996 · Phase 2 · registry result, not featured evidence · combination IM-Q4W injection site pain 99.1% injection site nodule 49.6% nasopharyngitis 47% NCT02120352 · Phase 2 · registry result, not featured evidence · combination IM-Q4W injection site pain 80% injection site nodule 50% nasopharyngitis 50% NCT02120352 · Phase 2 · registry result, not featured evidence · combination IM-Q8W injection site pain 96.5% nasopharyngitis 47% injection site nodule 40% NCT02120352 · Phase 2 · registry result, not featured evidence · combination IM-Q8W injection site pain 91.2% injection site nodule 35.3% covid-19 26.5% NCT02120352 · Phase 2 · registry result, not featured evidence · combination Q2M injection site pain 74.4% covid-19 33.3% upper respiratory tract infection 17.8% NCT03639311 · Phase 2 · registry result, not featured evidence · combination 30 mg headache 21.7% nausea 18.3% upper respiratory tract infection 13.3% NCT01641809 · Phase 2 · registry result, not featured evidence 30 mg upper respiratory tract infection 26.4% diarrhoea 13.2% rash 11.3% NCT01641809 · Phase 2 · registry result, not featured evidence 30 mg upper respiratory tract infection 31.9% back pain 12.8% oropharyngeal pain 12.8% NCT01641809 · Phase 2 · registry result, not featured evidence 60 mg headache 21.3% diarrhoea 18% nausea 18% NCT01641809 · Phase 2 · registry result, not featured evidence 60 mg upper respiratory tract infection 21.8% nausea 14.5% bronchitis 10.9% NCT01641809 · Phase 2 · registry result, not featured evidence 60 mg upper respiratory tract infection 27.5% anxiety 11.8% sinusitis 11.8% NCT01641809 · Phase 2 · registry result, not featured evidence 10 mg nausea 23.3% headache 21.7% diarrhoea 16.7% NCT01641809 · Phase 2 · registry result, not featured evidence 10 mg upper respiratory tract infection 17.3% depression 9.6% diarrhoea 9.6% NCT01641809 · Phase 2 · registry result, not featured evidence 10 mg diarrhoea 13% nasopharyngitis 10.9% gonorrhoea 8.7% NCT01641809 · Phase 2 · registry result, not featured evidence 30 mg dizziness 37.5% (placebo 0%) dyspepsia 25% (placebo 0%) headache 25% (placebo 0%) NCT00920426 · Phase 2 · registry result, not featured evidence 5 mg abdominal pain 0% (placebo 0%) abnormal dreams 0% (placebo 0%) blood bilirubin increased 0% (placebo 50%) NCT00920426 · Phase 2 · registry result, not featured evidence 30 mg atrioventricular block first degree 7.7% decreased appetite 7.7% headache 7.7% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 100% aspartate aminotransferase increased 50% blood creatine phosphokinase increased 50% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 100% injection site nodule 55.6% injection site erythema 44.4% NCT04484337 · Phase 1 · registry result, not featured evidence injection site haemorrhage 100% injection site nodule 100% injection site pain 100% NCT04484337 · Phase 1 · registry result, not featured evidence injection site erythema 72.7% injection site pain 72.7% injection site induration 45.5% NCT04484337 · Phase 1 · registry result, not featured evidence injection site induration 100% injection site pain 100% injection site bruising 50% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 75% headache 37.5% injection site swelling 37.5% NCT04484337 · Phase 1 · registry result, not featured evidence catheter site bruise 50% injection site erythema 50% injection site induration 50% NCT04484337 · Phase 1 · registry result, not featured evidence injection site erythema 100% injection site pain 94.4% headache 77.8% NCT04484337 · Phase 1 · registry result, not featured evidence injection site erythema 100% injection site pain 100% injection site pruritus 87.5% NCT04484337 · Phase 1 · registry result, not featured evidence · combination injection site erythema 100% injection site pain 100% injection site warmth 88.9% NCT04484337 · Phase 1 · registry result, not featured evidence · combination accident 100% injection site nodule 100% injection site pain 100% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 100% injection site swelling 70% headache 60% NCT04484337 · Phase 1 · registry result, not featured evidence 30 mg blood creatine phosphokinase increased 6.7% contusion 6.7% body temperature increased 0% NCT03149848 · Phase 1 · registry result, not featured evidence 300 mg + 30 mg body temperature increased 7.1% headache 7.1% hyperkeratosis 7.1% NCT03149848 · Phase 1 · registry result, not featured evidence · combination | 50 mg plus 600/300 mg once dailyh diarrhoea 22.7% nasopharyngitis 20.8% insomnia 17.9% NCT01263015 · Phase 3 · combination · HIV · phase 3 show 31 more results50 mg Once a Day upper respiratory tract infection 8% syphilis 7.1% viral upper respiratory tract infection 7.1% NCT01227824 · Phase 3 · HIV · phase 3 50 mg once daily viral upper respiratory tract infection 4.1% gastroenteritis 2.4% asthenia 1.6% NCT01449929 · Phase 3 insomnia/nightmares 3.9% alopecia 2% itching/rash/prurigo 2% NCT04880395 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 8.7% headache 8.1% urinary tract infection 6% NCT01910402 · Phase 3 · registry result, not featured evidence nausea 18.5% headache 11.7% diarrhoea 9.3% NCT01910402 · Phase 3 · registry result, not featured evidence covid-19 6.9% suspected covid-19 3.4% headache 3% NCT02831673 · Phase 3 · registry result, not featured evidence · combination headache 14.3% diarrhoea 14% nasopharyngitis 13.8% NCT02831673 · Phase 3 · registry result, not featured evidence · combination covid-19 6% syphilis 4% respiratory tract infection viral 3.2% NCT02831764 · Phase 3 · registry result, not featured evidence · combination diarrhoea 13.6% upper respiratory tract infection 13.1% nasopharyngitis 12.2% NCT02831764 · Phase 3 · registry result, not featured evidence · combination creatinine renal clearance decreased 83.9% blood creatinine increased 78.3% haemoglobin decreased 3.7% NCT03048422 · Phase 3 · registry result, not featured evidence · combination creatinine renal clearance decreased 89.8% blood creatinine increased 83.3% haemoglobin decreased 9.3% NCT03048422 · Phase 3 · registry result, not featured evidence · combination grade 3 bilirubinemia 0% NCT02263326 · Phase 3 · registry result, not featured evidence · combination 50 mg OD headache 53.8% upper respiratory tract infection 38.5% diarrhoea 30.8% NCT01499199 · Phase 3 · registry result, not featured evidence 50mg BID diarrhoea 21.4% (placebo 12.5%) headache 21.4% (placebo 6.3%) lymphadenopathy 21.4% (placebo 0%) NCT01568892 · Phase 3 · registry result, not featured evidence cns disturbances 0% NCT01837277 · Phase 2/3 · registry result, not featured evidence 50 mg BID abnormal loss of weight 10% blood pressure increased 10% headache 10% NCT05630872 · Phase 2 · registry result, not featured evidence acute psychosis 1.5% (placebo 0%) incident pulmonary tuberculosis 1.5% (placebo 0%) acute kidney injury 0% (placebo 3.1%) NCT03991013 · Phase 2 · registry result, not featured evidence insomnia 5.7% (placebo 0%) NCT03851588 · Phase 2 · registry result, not featured evidence haemoglobin decreased 33.3% alanine aminotransferase increased 16.7% aspartate aminotransferase increased 16.7% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 50% alanine aminotransferase increased 16.7% blood bilirubin increased 16.7% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 83.3% neutrophil count decreased 50% acne infantile 16.7% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 42.9% blood bilirubin increased 35.7% dermatitis diaper 21.4% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 56.3% neutrophil count decreased 31.3% blood bilirubin increased 25% NCT05406583 · Phase 1 · registry result, not featured evidence hypokalaemia 71.4% (placebo 71.4%) hypoglycaemia 42.9% (placebo 71.4%) vivid dreams 28.6% (placebo 0%) NCT04771754 · Phase 1 · registry result, not featured evidence hypokalaemia 62.5% (placebo 71.4%) cold 25% (placebo 14.3%) bloating 12.5% (placebo 0%) NCT04771754 · Phase 1 · registry result, not featured evidence 50mg/25mg headache 6.3% vessel puncture site bruise 6.3% vomiting 6.3% NCT03984838 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 3.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context differs: pooled versus combination.
- eTreatment context has not been resolved for both arms.
- fAssessment timepoints differ: 130 weeks versus 432 weeks.
- gPopulation comparability has not been reviewed for these studies.
- hPopulation comparability has not been reviewed for 39 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Cabotegravir/rilpivirine (Cabenuva)
show 2 more results
show 2 more results
show 1 more result
show 4 more results
show 6 more results
show 1 more result
show 1 more result
show 1 more result
show 6 more results
show 1 more result
+ 161 further endpoints in the CSV export.
Dolutegravir
show 2 more results
show 1 more result
+ 85 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cabotegravir/rilpivirine (Cabenuva)'s landscape · Dolutegravir's landscape